Literature DB >> 16029126

Familial nonmedullary thyroid cancer.

Cord Sturgeon1, Orlo H Clark.   

Abstract

Familial nonmedullary thyroid cancer (FNMTC) is a syndrome of familial clustering of thyroid cancers of follicular cell origin. It is characterized by multifocality, early onset, more recurrences, and a higher degree of aggressiveness than nonfamilial thyroid cancers of follicular cell origin. An autosomal dominant inheritance pattern with reduced penetrance appears likely in most pedigrees. Although several candidate genes responsible for isolated clinical variants of FNMTC have been identified in single families, the gene(s) responsible for the vast majority of FNMTC cases has yet to be identified. Members of FNMTC cohorts should be followed longitudinally with physical examination and ultrasonography, and aggressively treated when cancer is diagnosed. When cancer is diagnosed, total thyroidectomy should be performed, and most patients should have a prophylactic central neck dissection and a therapeutic lateral functional neck dissection, postoperative radioiodine ablation and thyroid-stimulating hormone (TSH) suppressive therapy. Close follow-up with stimulated thyroglobulin levels, neck ultrasounds, and radioiodine scans are also central to the management strategy.

Entities:  

Mesh:

Year:  2005        PMID: 16029126     DOI: 10.1089/thy.2005.15.588

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.

Authors:  Young Joo Park; Hwa Young Ahn; Hoon Sung Choi; Kyung Won Kim; Do Joon Park; Bo Youn Cho
Journal:  Thyroid       Date:  2012-01-26       Impact factor: 6.568

2.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 3.  Controversies in familial thyroid cancer 2014.

Authors:  Orlo H Clark
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

4.  Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation.

Authors:  Andreas Hillenbrand; Jan-Erik Varhaug; Michael Brauckhoff; Rumen Pandev; Sabine Haufe; Cornelia Dotzenrath; Roswitha Köberle; Rainer Hoffmann; Günther Klein; Martina Kadmon; Thomas Negele; Tatjana Hagieva; Doris Henne-Bruns; Markus Luster; Theresia Weber
Journal:  Langenbecks Arch Surg       Date:  2010-08-05       Impact factor: 3.445

5.  Surgical Management of Familial Papillary Thyroid Microcarcinoma: A Single Institution Study of 94 Cases.

Authors:  Tae-Yon Sung; Yu-mi Lee; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

6.  A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.

Authors:  Carolina Pires; Inês Jorge Marques; Daniela Dias; Ana Saramago; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2021-03-08       Impact factor: 3.633

7.  Clinical Analysis of Familial Nonmedullary Thyroid Carcinoma.

Authors:  Qiang Zhang; Shuai Yang; Xian-ying Meng; Guang Chen; Ren-zhu Pang
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

Review 8.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 9.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

10.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.